A New Study Suggests Energy4Life’s Bioenergetic Wearable Device May Have Positive Effects on Cellular Membrane

The study, led by Professor Hemal Patel, Vice-Chair of Medical Research at University of California at San Diego, observed positive unique and cell-specific effects on cellular membrane structure, mitochondrial function, oxidative stress, and viral infection protection

A recent study by researchers at the University of California at San Diego, found that a bioenergetic wearable device delivering biological information to the body using photons, has positive effects on the physiology of live cell cultures. This study has found these results may lead to improved energy levels and sleep quality, reduce stress, and help people better manage their emotions.

A cutting-edge technology, developed and created by Energy4Life, bioenergetic wearable devices use digitized biological information to help restore the body’s energy.

“Our bioenergetic wearables are designed to communicate directly to the body, thus triggering its self-repair system,” said Harry Massey, founder and CEO of Energy4Life. “Digitized biological information allows you to help turn on the body’s self-repair system – impacting the physics of the body – which in turn directs all other activity of the body,” stated Massey.

“We are pleased to see Dr. Patel’s research begin to prove what we have witnessed in hundreds of thousands of patients. Ancient medical practices like traditional Chinese Medicine and acupuncture have long believed that many health conditions occur because of an energetic imbalance. We actually know the body does this because of the biological responses to electromagnetic fields, as well as light and sound, both shown to alter the expression of DNA,” explained Massey.

Some of the key findings from the study include:

  • Mitochondrial density increased by up to 50%
  • Mitochondria were protected from reactive oxygen species damage by up to 67%, thus reducing cellular oxidative stress
  • Possible protection against certain viral infections.

“We know that mitochondria are the cell’s powerhouse, creating ATP – the energy that powers a cell and all its unique functions. This study reveals that bioenergetics could be the next healthcare breakthrough for those suffering from fatigue, autoimmune disorders, and other diseases of aging – a breakthrough desperately needed and deserved,” continued Massey.

To obtain quantifiable results on how the bioenergetic wearable impacts cellular physiology, researchers imprinted culture mediums with biological information and performed a battery of in vitro experiments using various types of cells, including cardiac muscle, skeletal muscle, neural stem cells, and lung epithelial cells. Researchers used several different types of biological information.

Information may be administered through a special preparation of mineralized water (“imprinted” with photons and magnetic fields), or imprinted directly into the body via electronic equipment. This equipment includes the NES Health miHealth device and the GEM wearable, a new device slated for release in late 2023 by Massey’s newest company, Energy4Life.

The wearable is based on proprietary technology and extensive research spanning more than 30-years in the field-based control system, and based in physics opposed to the chemical-based system that most modern medicine relies on.

Observations from this study are the first of its kind. More comprehensive observations are necessary to understand the mechanisms underlying these changes.

Further studies are being conducted on how the wearable may aid energy and emotional management, reduce stress, and improve sleep and energy. More here.


Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  

By using this website you agree to accept Medical Device News Magazine Privacy Policy